Browse Articles

Discover research articles across all indexed journals

Resistance development in pink bollworm (Pectinophora Gossypiella Saunders) against Bt cotton and its’ establishment as mid season pest in India

Scientific Reports Rishi Kumar, B. V. Bhede, Debashis Paul et al. Feb 27, 2025 DOI: 10.1038/s41598-025-89575-z

Monitoring CH: time to move beyond VAF?

Blood Lachelle D. Weeks Feb 27, 2025 DOI: 10.1182/blood.2024027472

Author Correction: Characterization of the natural fibers extracted from the aninga’s stem and development of a unidirectional polymeric sheet

Scientific Reports Jucelio Lima Lopes Junior, David Rodrigues Brabo, Everton Leandro Santos Amaral et al. Feb 27, 2025 DOI: 10.1038/s41598-025-91974-1

Novel treatment strategies for chronic myeloid leukemia

Blood Nataly Cruz-Rodriguez, Michael W. Deininger Feb 27, 2025 DOI: 10.1182/blood.2024026312

Abstract Starting with imatinib, tyrosine kinase inhibitors (TKIs) have turned chronic myeloid leukemia (CML) from a lethal blood cancer into a chronic condition. As patients with access to advanced CML care have an almost normal life expectancy, there is a perception that CML is a problem of the past, and one should direct research resources elsewhere. However, a closer look at the current CML landscape reveals a more nuanced picture. Most patients still require life-long TKI therapy to avoid recurrence of active CML. Chronic TKI toxicity and the high costs of the well-tolerated agents remain challenging. Progression to blast phase still occurs, particularly in socioeconomically disadvantaged parts of the world, where high-risk CML at diagnosis is common. Here, we review the prospects of further improving TKIs to achieve optimal suppression of BCR::ABL1 kinase activity, the potential of combining different classes of TKIs, and the current state of BCR::ABL1 degraders. We cover combination therapy approaches to address TKI resistance in the setting of residual leukemia and in advanced CML. Despite the unprecedented success of TKIs in CML, more work is needed to truly finish the job, and we hope to stimulate innovative research aiming to achieve this goal.

NLRP3 overexpression exacerbated synovium tissue degeneration in juvenile collagen-induced arthritis

Scientific Reports Fater A. Khadour, Younes A. Khadour, Tao Xu Feb 27, 2025 DOI: 10.1038/s41598-025-86720-6

Hypercalcemia in MGUS: keep the differential diagnosis broad

Blood Hira Mian, Alissa Visram Feb 27, 2025 DOI: 10.1182/blood.2024027928

Impact of the dispersive patch placement on dissipated power in radiofrequency ablation for pulmonary vein isolation via a virtual patient study

Scientific Reports Minha Anees, Zoraida Moreno Weidmann, David Viladés Medel et al. Feb 27, 2025 DOI: 10.1038/s41598-025-90158-1

Abstract Radiofrequency ablation (RFA) is a minimally invasive technique for treating arrhythmias by interrupting abnormal electrical signals in the heart. Through a catheter tip, it delivers an alternating current that flows through the heart muscle tissue and the blood to a dispersive patch on the patient’s skin. This study aims to test the hypothesis that the placement of the dispersive patch affects the efficacy and safety of RFA. By optimizing the patch position, the procedure could be made more effective and less risky for patients. A 3D in-silico model, based on patient imaging data, was developed to examine the effects of dispersive patch (DP) positioning on electric field distribution within cardiac tissue and the torso during RFA. We conducted 80 computer simulations using a CT-segmented torso model, exploring various DP and electrode configurations while applying standard (25 W) and high (90 W) power settings. For each configuration, we assessed the effectiveness of the DP in delivering power to cardiac tissue near the electrode. The main finding indicates that DP efficacy is significantly influenced by the current delivered to cardiac tissue. Notably, using an anterior patch during ablation proved more effective for the posterior left atrium compared to a posterior patch.

NGAL: a new link between thrombosis and hemostasis

Blood Badr Kilani, Konstantin Stark Feb 27, 2025 DOI: 10.1182/blood.2024027586

Metabolic profiling and gene expression analyses shed light on the cold adaptation mechanisms of Saposhnikovia divaricata (Turcz.) Schischk

Scientific Reports Ming Jiang, Yue Pan, Kanchao Yu et al. Feb 27, 2025 DOI: 10.1038/s41598-025-91094-w

Introduction to a series of reflections on a quarter century of TKIs for CML

Blood Brian J. Druker Feb 27, 2025 DOI: 10.1182/blood.2024026515

This Review Series highlights the transformative impact of tyrosine kinase inhibitors (TKIs) on therapy for chronic myeloid leukemia (CML) in the last 25 years. Brian J. Druker introduces the series by providing a Perspective that recalls the initial presentation at the 1999 American Society of Hematology annual meeting, revealing a 100% response rate at effective doses of imatinib in the phase 1 study. Guilhot and Hehlmann review long-term outcomes of patients with CML treated with TKIs in major studies and note that survival of patients with CML now approaches that of the general population. Hughes et al address the issue of treatment-free remission and explore the criteria for safely discontinuing TKIs for select patients. Finally, Cruz-Rodriguez and Deininger discuss mechanisms of resistance, emerging therapeutic strategies, and the promise of BCR::ABL1 degraders and TKI combinations.

Complement activation and vascular complications after pediatric allogeneic hematopoietic stem cell transplantation

Scientific Reports Lilli Leimi, Kim Vettenranta, Seppo Meri Feb 27, 2025 DOI: 10.1038/s41598-025-91455-5

Anti-CD19 antibody cotreatment enhances serial killing activity of anti-CD19 CAR-T/-NK cells and reduces trogocytosis

Blood Seung Kwon Koh, Hyojin Kim, Bohwa Han et al. Feb 27, 2025 DOI: 10.1182/blood.2024025673

Abstract Anti-CD19 chimeric antigen receptor (CAR)–engineered T and natural killer (NK) cell therapies have revolutionized the treatment of B-cell malignancies, but challenges including CD19 antigen loss greatly hinder their full therapeutic potential. Here, we revealed that cotreatment with anti-CD19 monoclonal antibody enhances antitumor activity of anti-CD19 CAR-T and -NK cells. Even though the treated antibody interferes with CD19 antigen binding of CAR, it significantly induces rapid detachment of anti-CD19 CAR effector cells from target cells, facilitating improved serial killing. This reduced interaction between CAR effector cells and target cells also leads to the alleviation of CAR-mediated trogocytosis. Interestingly, cotreatment with anti-CD19 antibody reveals time-dependent effects on the antitumor activity of anti-CD19 CAR-T cells, characterized by a reduction in early T cell activation followed by sustained high activity during prolonged exposure to target cells. This temporal modulation ultimately results in enhanced antitumor potency in vivo. These findings underscore the improved therapeutic efficacy achieved by combining anti-CD19 antibody with anti-CD19 CAR-T or -NK cells against B-cell malignancies.

Comparison of accumulation rates of beta-amyloid tracers and their relationship with cognitive changes

Scientific Reports Soo Hyun Cho, Heekyoung Kang, Hongki Ham et al. Feb 27, 2025 DOI: 10.1038/s41598-025-90642-8

Long-term outcomes of tyrosine kinase inhibitors in chronic myeloid leukemia

Blood François Guilhot, Rüdiger Hehlmann Feb 27, 2025 DOI: 10.1182/blood.2024026311

Abstract Long-term outcomes with tyrosine kinase inhibitors (TKIs) show that their impact on chronic myeloid leukemia (CML) is sustained as shown by 13 studies with 5- to 14-year-follow-up, and numerous shorter-term studies of newly diagnosed chronic-phase CML. Twenty-five years of imatinib (IM) treatment confirm its beneficial effect on survival and possible cure of CML. Large, randomized, academic, treatment-optimization studies have confirmed and extended the pivotal International Randomized Study on Interferon and STI571. The 3 academic trials in Germany, France, and the United Kingdom did not show benefit of the IM-interferon (IFN) combination, despite the immunomodulatory properties of IFN. Second-generation (2G) TKIs induce responses faster than IM and recognize IM-resistance mutations but do not prolong survival compared with IM. Adverse drug-related reactions (ADRs) limit the general use of 2GTKIs despite frequent but mostly mild IM-ADRs. Molecular monitoring of treatment efficacy has been established serving as an example for other neoplasms. Comorbidities, transcript type, and the negative impact of high-risk additional chromosomal abnormalities were addressed. A new prognostic score (European Treatment and Outcome Study long-term survival score) accounts for the fact that the majority of patients with CML die of other causes. Non-CML determinants of survival have been identified. Large and long-term observational studies demonstrate that progress with CML management has also reached routine care in most but not all instances. Despite merits of 2GTKIs, IM remains the preferred treatment option for CML because of its efficacy and superior safety.

The calcineurin-responsive transcription factor Crz1 regulates the expression of CMK2 via a sole CDRE site in its promoter in budding yeast

Scientific Reports Linghuo Jiang, Yiying Gu, Yongqiang Jiang et al. Feb 27, 2025 DOI: 10.1038/s41598-025-91599-4

Novel interferon-based antimyeloma activity

Blood Arthur Bobin, Xavier Leleu Feb 27, 2025 DOI: 10.1182/blood.2024027417

Effect of color visual stimulation by colored glass lenses on postural control

Scientific Reports Wenyu Zhang, Hiroaki Takada, Manuel Hettmannsperger et al. Feb 27, 2025 DOI: 10.1038/s41598-025-88102-4

Approaching hypercalcemia in monoclonal gammopathy of undetermined significance: insights from the iStopMM screening study

Blood Ástrún Helga Jónsdóttir, Helga Ágústa Sigurjónsdóttir, Sigrún Thorsteinsdóttir et al. Feb 27, 2025 DOI: 10.1182/blood.2024025624

Abstract Hypercalcemia in monoclonal gammopathy of undetermined significance (MGUS) presents a clinical challenge because it may indicate progression to multiple myeloma (MM) but could also be due to a multitude of unrelated disorders. To inform the approach to this clinical challenge, we conducted a nested cohort study within the Iceland Screens, Treats, or Prevents Multiple Myeloma screening study. Of the 75 422 Icelanders aged 40 years and above who underwent screening for MGUS, we included 2546 with MGUS who were in active follow-up, including regular serum calcium measurements. In total, 191 individuals (7.5%) had hypercalcemia detected at least once, of whom 93 had persistent hypercalcemia (48.7%). MM was found in 3 participants with persistent hypercalcemia (3.2%); all had concurrent bone disease and other end-organ damage. The most common causes of hypercalcemia were primary hyperparathyroidism (56.0%) and malignancies other than MM (16.0%). In this first comprehensive study on hypercalcemia in MGUS, we observed that hypercalcemia rarely indicated MGUS progression and never in the absence of other symptoms of MM. More than half of hypercalcemia cases were transient, and the underlying causes were similar to those in the general population. We conclude that hypercalcemia in MGUS should be approached in the same way as in those without MGUS.

Reynolds rules in swarm fly behavior based on KAN transformer tracking method

Scientific Reports Qi Yang, Jiajun Ji, Ruomiao Jing et al. Feb 27, 2025 DOI: 10.1038/s41598-025-91674-w

The evolution of treatment-free remission

Blood Timothy P. Hughes, Agnes S. M. Yong, David M. Ross Feb 27, 2025 DOI: 10.1182/blood.2024026310

Abstract One of the most remarkable achievements of the tyrosine kinase inhibitor (TKI) era has been the capacity to induce deep molecular remissions that are sustainable off therapy in patients with chronic myeloid leukemia (CML), that is, treatment-free remission (TFR). TFR was first described in a handful of patients within 3 to 4 years of imatinib approval. In 2004, TFR was tested in a small French pilot study, followed soon after by the French STIM and Australasian TWISTER studies. These early trials demonstrated that TFR was achievable but also showed that rapid relapse was equally likely. Perhaps the most critical observation was that relapsing patients could be rapidly and safely returned to deep molecular remission after restarting therapy, minimizing the risk associated with TFR attempts. Consensus criteria for TFR eligibility were established soon after those studies were reported. Over the past decade, TFR criteria have been broadened, key predictive markers of success identified, and overall safety of TFR in the wider clinical community confirmed. Despite this progress, TFR is still only achieved in a fraction of patients with CML globally. Over the next decade, the focus will be making TFR the mainstream pathway for as many patients as possible as well as scaling back the duration of therapy required. More potent, better targeted TKIs, and immune modulation will likely have a significant impact. Predictive assays should enable most patients who attempt TFR to do so with a high probability of success. Ultimately TFR should be seen as the first step on an ambitious pathway toward cure for patients with CML.